Research Center in Sport Sciences, Health and Human Development (CIDESD) & Sport Sciences Department, Universidade da Beira Interior, Covilhã, Portugal.
Associação de Cuidados de Suporte em Oncologia, Sanfins, Portugal.
Syst Rev. 2019 Oct 24;8(1):239. doi: 10.1186/s13643-019-1154-x.
Cardiotoxicity is a known complication and one of the most adverse effects from the use of conventional treatments such as anthracyclines and trastuzumab in breast cancer (BC) care. This phenomenon has been associated with the restriction of therapeutic options and the increase of cardiovascular complications, which may compromise the survival of patients. Implementation of preventive strategies is an important approach for the management of this issue. Physical exercise has been proposed as a non-pharmacological strategy to counteracting cardiotoxicity. The aim of this protocol is to describe the rationale and methods for a systematic review of published randomized controlled trials (RCTs) that have analysed the effects of physical exercise on outcomes of cardiac (dys)function in women with BC undergoing neoadjuvant or adjuvant treatment containing anthracyclines and/or trastuzumab.
This is a protocol for a systematic review reported according to the PRISMA-P 2015 checklist. Randomized controlled trials (RCTs) will be included. The literature will be screened on MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, ISI Web of Science and Scopus. The risk of bias of the included RCTs will be assessed using the Cochrane Collaboration's tool. The primary outcomes will be systolic function (left ventricular ejection fraction), diastolic function (E/A' ratio, deceleration time of early left ventricular filling, isovolumetric relaxation time, E/E' septal and lateral ratio) and myocardial deformation imaging outcomes (strain and strain rate [measured in longitudinal, radial, or circumferential directions]). Secondary outcomes will be cardiac biomarkers (troponin I or T, high-sensitivity troponin I or T, brain natriuretic peptide, amino terminal of B-type natriuretic peptide). Data will be descriptively reported, and quantitative synthesis will also be considered if the included studies are sufficiently homogenous.
This systematic review will help to understand the effectiveness of physical exercise on counteracting cardiotoxicity related to anticancer therapies in women with BC.
PROSPERO CRD42018096060.
心脏毒性是一种已知的并发症,也是乳腺癌(BC)治疗中使用常规治疗方法(如蒽环类药物和曲妥珠单抗)的最严重副作用之一。这种现象与治疗选择受限和心血管并发症增加有关,可能危及患者的生存。实施预防策略是管理这一问题的重要方法。运动已被提议作为对抗心脏毒性的非药物策略。本方案旨在描述对已发表的随机对照试验(RCT)进行系统评价的基本原理和方法,这些 RCT 分析了运动对接受含蒽环类药物和/或曲妥珠单抗的新辅助或辅助治疗的 BC 女性心脏(功能)障碍结局的影响。
这是根据 PRISMA-P 2015 清单报告的系统评价方案。将纳入随机对照试验(RCT)。将在 MEDLINE、EMBASE、Cochrane 中央对照试验注册库、ISI Web of Science 和 Scopus 上筛选文献。将使用 Cochrane 协作工具评估纳入 RCT 的偏倚风险。主要结局将是收缩功能(左心室射血分数)、舒张功能(E/A'比值、早期左心室充盈减速时间、等容舒张时间、E/E'间隔和侧壁比值)和心肌变形成像结局(应变和应变率[在纵向、径向或圆周方向测量])。次要结局将是心脏生物标志物(肌钙蛋白 I 或 T、高敏肌钙蛋白 I 或 T、脑利钠肽、B 型利钠肽氨基末端)。将描述性报告数据,如果纳入的研究足够同质,也将考虑进行定量综合分析。
本系统评价将有助于了解运动对对抗 BC 女性抗癌治疗相关心脏毒性的有效性。
PROSPERO CRD42018096060。